Speakers

Paolo Arosio is a Tenure-​Track Assistant Professor in Biochemical Engineering at the Institute for Chemical and Bioengineering at ETH Zurich since 2016. He received his master degree in Chemical Engineering from the Politecnico di Milano in 2007 and his doctoral degree from ETH Zurich in...

Samuel Azuz is a Clinical Pharmacologist MD and Senior Registrar at the Department of Clinical Pharmacology Aalborg University Hospital, Denmark. Member of the CLL and HIV expert committees, the Danish Medicines Council. Samuel's fields of interest include: Pharmacoeconomics, the biosimilar...

Martin obtained a PhD in Biochemistry from the University of Konstanz in a joint program with the University of Michigan. After postdoctoral training at the University of Washington, Martin joined Amunix Pharmaceuticals to work on long-acting protein therapeutics. In his current role at Roche, he...

Dr George Badescu is Vice President Scientific Affairs at Heidelberg Pharma and has over 15 years of experience in the biotechnology sector. He most recently served as Vice President Scientific Affairs at Abzena Plc where he led the scientific promotion and commercialization of Abzena?s...

Alain Beck is Senior Director, Biologics CMC and developability, Pierre Fabre Laboratories (FR). He is associated editor of mAbs (USA) and mAbDesign advisor board chairman (www.mabdesign.fr). He has contributed to the R&D of immuno-oncology mAbs, clinical stages mAbs and ADCs in oncology...

Alun Bedding is currently the Global Head of Methods, Collaboration and Outreach in the Data and Statistical Sciences Department.  He has worked in the pharmaceutical industry for over 30 years and specializes in early clinical development, most specifically dose-finding, dose-escalation, adaptive...

Dr. Roger R. Beerli (CSO of NBE-Therapeutics AG, a wholly owned subsidiary of Boehringer-Ingelheim) has over 20 years of experience in the discovery, engineering and preclinical development of antibody-based therapeutics. Before he joined NBE-Therapeutics AG, he led therapeutic antibody development ...

​​​​​​Davide Bertoldo studied Pharmaceutical Biotechnology at the University of Padova (Italy) and University of Liège (Belgium). In 2012, he joined the Laboratory of Therapeutic Proteins and Peptides at EPFL (Switzerland). During his PhD, he developed peptide macrocycles targeting a variety of...

Jamie Biddlecombe is a Director in Biopharmaceutical Development at AstraZeneca.  He has 15+ yrs experience working primarily in drug product development.  He has been a formulation scientist designing liquid and lyophilised formulations, before specialising in fill-finish process development and...

José is a Science and People Lead in the Mass Spectrometry department of Large Molecule Research at Roche Pharma Research and Early Development (pRED). He leads large molecule drug discovery projects, from an initial concept to Phase I, and develops hands-on state of the art MS methods for...

A physician by training and an expert in immunobiology and drug development, Ezio Bonvini is the Senior Vice President of Research and Chief Scientific Officer at MacroGenics, Inc., which he joined in 2003 after a career at the National Cancer Institute, NIH, and the Center for Biologics Evaluation ...

Andrew Bradbury is Chief Scientific Officer of Specifica, a company he founded in 2016, after retiring from LANL. He trained in medicine at the Universities of Oxford and London and received his PhD from the University of Cambridge at the MRC Laboratory of Molecular Biology, under the guidance of...

Director Protein Science      Bioprocess & Analytical Development Germany  Responsible for the development of state-of-the-art purification processes for CMB client projects including process transfers to the global BioBU production network.Responsible for driving project independent...

Patrick Bulau is principal scientist leading a team performing physico-chemical analyses with special focus on mass spectrometric technologies at Roche Pharma Technical Development in Penzberg, Germany. In addition to his responsibility for the analytics of drug substance development products he is ...

Sebastian Bunk is a senior director at Immatics where he leads a team developing a pipeline of bispecific T cell-engaging receptor (TCER®) molecules. After joining Immatics in 2014, Sebastian focused on the establishment of innovative technologies for engineering of T-cell receptors and generation...

In 2016, after receiving his PhD in Chemistry at the University of Strathclyde in Glasgow, Dan began working at MedImmune in Cambridge UK, where he utilised computational approaches for therapeutic protein design. In August of 2018, he joined Schrödinger as an Applications Scientist, where he now...

Samuele Cazzamalli studied Medicinal Chemistry at the University of Milan. During his doctoral studies at ETH Zürich in the group of Prof. Dario Neri (2015-2018), Samuele has generated novel Antibody-Drug Conjugate, Small Molecule-Drug Conjugate and Small Molecule-Radio Conjugate products for...

Francis P. Crawley is the Executive Director of the Good Clinical Practice Alliance – Europe (GCPA) and the Strategic Initiative for Developing Capacity in Ethical Review (SIDCER) located in Leuven, Belgium. Francis has expertise in EU, US, international and country-specific ethics, GCP, law, and...

I am currently a Senior Scientist at Amgen in the Therapeutic Area group, primarily working on developing bispecific antibodies and T cell engagers for immuno-oncology. Before Amgen, I was at Teneobio since July 2019 as Scientist III (and later Senior Scientist) in the Pre-Clinical Assays...

Dr. Dimitrov graduated and completed his PhD at the University of Sofia, Sofia, Bulgaria, and thereafter he worked in the Bulgarian Academy of Sciences where he defended his ScD and was Professor of Biophysics until he joined the National Cancer Institute (NCI) of the National Institutes of Health...

A biochemist by training, Achim has been working with bispecific antibodies or ADCs and technology development for their effective screening. In one flavour, screening of such and further complex NBEs is realized applying versatile microfluidics and in part in conjunction with mammalian libraries...

Christoph Esslinger is the CSO and scientific founder of Memo Therapeutics AG and a pioneer of the discovery of therapeutic antibody candidates directly from human donors for immunotherapy of Alzheimer’s Disease and cancer. Prior to founding Memo Therapeutics AG he held senior positions at CT...

Since October 2020, Dr. Andreas Evers is working as Computational and Structural Bioinformatician on NBEs at Merck Healthcare KGgaA. He obtained his PhD in Computational Chemistry with Prof. Gerhard Klebe at Philipps University of Marburg in 2000. He joined Sanofi in 2003, first working in the area ...

Victor Greiff is an Associate Professor at the University of Oslo (Department of Immunology) since January 2018. His group develops machine learning, computational and experimental tools for analyzing antibody and T-cell repertoires to facilitate the in silico design of immune receptor-based...

Eliott is a Partner at Nodes Advisors where he leads investments at the cross section of biology, computer sciences and engineering.

Dr. Soraya Hölper works as a Lab Head for Mass Spectrometry for Sanofi in Frankfurt am Main. She is acquainted with the analysis of complex therapeutic antibodies within the Biologics Research division. After studying biochemistry at the Goethe University of Frankfurt am Main, Soraya did her...

Beat A. Imhof is professor and was chair of the Department of Pathology and Immunology for more than 10 years at the Medical Faculty, University of Geneva, Switzerland. He studied Biochemistry in Zurich, Switzerland, did then his PhD at the Friedrich Miescher Laboratory of the Max Planck Institute...

I graduated in 1989 from King´s College London with a Ph.D. in Biochemistry, followed by postdoctoral research in Wye College (University of London), then the University of Kent; the latter a joint project with the Advanced Centre for Biochemical Engineering at University College London. Following ...

Dr. Keirstead is an internationally known stem cell expert and has led therapy development for late stage cancers, immune disorders, motor neuron diseases, spinal cord injury and retinal diseases. He is the CEO of AIVITA Biomedical. He was previously CSO of Caladrius which acquired California Stem...

Dan Bach Kristensen holds a Ph.D. in biology and B.Sc. degree in chemistry. Dan is specialized in protein chemistry and mass spectrometry, which he initially applied in the field of proteome research in Japan and later in Denmark. For the last 15 years Dan has been working with analytical...

Anne Ljungars holds a PhD in Immunotechnology from Lund University, Sweden and has 20+ years of experience from biotech industry, latest from BioInvent International AB, Sweden where she has coordinated discovery efforts in several antibody drug projects, presently in preclinical or clinical...

Andrea Marschall studied Molecular Biotechnology at Heidelberg University, gained a PhD in Stefan Dübel's lab on targeting antibodies into living cells, continuing with Postdoctoral research at the Helmholtz Centre for Infection Research in Braunschweig (Germany) and at Brandeis University in...

Fionnuala received her PhD (Microbiology) from Trinity College Dublin in 2002.  Her post-doctoral studies were carried out at Wyeth Pharmaceuticals (NY) where she worked on S. aureus antibiotic resistance mechanisms.  She then transferred to the Global Biologics organization at Wyeth...

Enkelejda's research at the School of Life Sciences FHNW focuses on the use of computer science and artificial intelligence for drug discovery and personalized medicine. In doing so, she has a bridge function that is intended to link different life sciences processes with computer science.

Dario Neri was born in Rome on 1. May 1963 and grew up in Siena (Italy). He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry from the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich. After a post-​doctoral...

My research group is focused on protein engineering of calcium binding proteins for biotechnological applications. We apply structural biology analysis, proteomics tools and biophysical methods to develop new technology and our work is aimed at improving the molecular toolbox available to...

Benjamí Oller-Salvia is Assistant Professor at IQS School of Engineering ? Ramon Llull University in Barcelona (Spain). He obtained his PhD at the University of Barcelona, conducting research in Prof. Ernest Giralt?s laboratory at the Institute for Research in Biomedicine (IRB Barcelona). His PhD...

Dhaval Patel leads UCB's research organization with the main goal of bringing scientific innovation to patients and helping them live the life they choose.

Niccolò Pengo joined Mabylon in March 2019. He holds a PhD from the San Raffaele University in Milan with studies on B-cell immunology and worked as a post-doctoral fellow at University College London and as a Senior Scientist at UCB Pharma in the UK. During his research both in academia and...

Dr. Reichert, Executive Director of The Antibody Society, is an internationally-recognized expert in the development of antibody and peptide therapeutics. She is Founder and Managing Director of Reichert Biotechnology Consulting LLC, a biopharmaceutical business intelligence research firm, and...

I am heading a research group at the department of Protein science at the KTH School of Engineering sciences in Chemistry, Biotechnology and Health. We are a young group with four great PhD students, two excellent technicians, one extraordianary fantastic labmanager and two researchers. Our...

Nicolas Sabarth is heading a biotherapeutics discovery group at Boehringer-Ingelheim Vienna, Austria. He received his PhD from the Max-Planck-Institute for Infection Biology, Germany.  Since then, he held positions of increasing responsibility in the R&D departments of...

Aaron is CSO of Twist Bioscience and is a proven biologics leader adept at managing teams to discover novel first-in-class antibody therapeutics.  Prior to Twist, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovers novel antibody therapeutics ...

Dr. Thomas Schirrmann is CEO of YUMAB and COO of Corat Therapeutics. He is biochemist by training and holds a PhD in immunology. He has more than 20 years expertise in research for immunotherapies and antibody technologies and published 70+ scientific articles. Thomas is co-founder and CEO of...

Dr. Thorsten Schmidt joined Sanofi in 2002. He is currently the Head of the German Biologics Research Platform in the area of protein therapeutics. He is in this role since 2016 and responsible for a team of 60 scientists working on the design, the production and the analysis of next-generation...

Dr. Schnitzer, M.D. has devoted more than 30 years to understanding vascular endothelial cell barrier function and drug delivery in medicine, specifically how best to overcome this barrier to improve therapeutic impact of drugs in cancer, lung and other diseases. His lab currently focuses on drug...

Peter Senter joined Seattle Genetics in August 1998 and has served as Vice President, Chemistry since September 2002. In February 2009, Dr. Senter was recognized as the company's first Distinguished Fellow. He leads Seattle Genetics' chemistry department, which carries out research in...

Philipp Spycher is the co-founder and CEO of Araris Biotech AG. Philipp incorporated Araris after winning the PSI Founder Fellowship as well as several other prices and grants to commercialize the Araris Linker Technology. During his post-doctoral work at the Paul Scherrer Institute...

Dr. Pawel Stocki is the Director of Research at Ossianix. At Ossianix we are utilising single domain shark antibody fragments to tackle the problem of therapeutic biologics delivery across Blood Brain Barrier. We focus on development and innovation of phage libraries and selection...

Greg M. Thurber is an Assistant Professor of Chemical Engineering and Biomedical Engineering at the University of Michigan. His work focuses on applying fundamental biotransport principles to design novel therapeutics and molecular imaging agents. These widely applicable techniques have found use...

Paul van Bergen en Henegouwen studied biology at the University of Amsterdam and received his PhD in 1986 at the Utrecht University. Postdoctoral training was performed at the Utrecht University in the group of prof. Dr. A.J. Verkleij, in Toulouse, France in the group of prof. dr. H. Chap, ISERM...

Marjolein van Egmond's laboratory studies antibody activation of innate myeloid immune cells, macrophages and neutrophils, with emphasis on understanding the role of immunoglobulin A (IgA) in physiology and pathology. Her groups research focuses specifically on (1) the contribution of abnormal...

The Ward laboratory is run jointly with the laboratory of Professor Raimund Ober. The research is directed towards taking a highly interdisciplinary approach to generate effective therapeutics for autoimmunity and cancer. This involves a combination of antibody/protein engineering, fluorescence...

Thomas Wiese serves Roche in the role of a Principal Medical Director and Clinical Expert Team Leader. He is a board certified Pediatric Psychiatrist with 7 years of experience in clinical practice, clinical research and 6 years in pharmaceutical clinical drug development. Thomas is also trained...

Dr. Gordana Wozniak Knopp has received her PhD in Biochemistry and Molecular Biology from Medical University of Ljubljana, Slovenia. In her post-doctoral studies at the University of Natural Resources and Life Sciences (BOKU), Vienna, she got acquainted with display library methods and development...

Jens Wuerthner is a physician scientist and currently holds the position of Head of Clinical Development EU for ADC Therapeutics in Lausanne, Switzerland. He is a licensed physician in Germany, Switzerland and the UK and a fellow of the Faculty of Pharmaceutical Medicine, UK. Dr. Wuerthner...

Stefan received his PhD in 2015 from the Technische Universität of Darmstadt, Germany, where he worked in the Group of Harald Kolmar in the field of protein engineering of non-canonical antibodies. During his PhD he spent some time at Scripps Institute, La Jolla (USA) working in the lab of Vaughn...

Iwan Zimmermann is one of the founders and Chief Scientific Officer of Linkster Therapeutics. Iwan has over 12 years of experience with single domain antibodies and the biology of ion channels and transporters. Prior to co-founding Linkster Therapeutics, Iwan conducted research as platform leader...